Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSC Detection in AML
NCT02927938Phase 3Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cytarabine in acute myeloid leukemia (AML), sponsored by Wake Forest University Health Sciences. Primary endpoint: Relapse Free Survival at 2 years. Started Sep 2016; status: terminated.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02927938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927938.